QID 243134

Date Published: 2024-03-27

QID 243134: Red Hat Update for nodejs:18 (RHSA-2024:1510)

Node.js is a software development platform for building fast and scalable.network applications in the javascript programming language...Security Fix(es):

    nodejs: reading unprocessed http request with unbounded chunk extension allows dos attacks (cve-2024-22019).
    Nodejs: vulnerable to timing variant of the bleichenbacher attack against pkcs#1 v1.5 padding (marvin) (cve-2023-46809).
    Nodejs: code injection and privilege escalation through linux capabilities (cve-2024-21892).
Affected Products:
    Red Hat enterprise linux for x86_64 8 x86_64.
    Red hat enterprise linux for ibm z systems 8 s390x.
    Red hat enterprise linux for power, little endian 8 ppc64le.
    Red hat enterprise linux for arm 64 8 aarch64.
.

Note: The preceding description block is extracted directly from the security advisory. Using automation, we have attempted to clean and format it as much as possible without introducing additional issues.

Successful exploitation of this vulnerability could lead to a security breach or could affect integrity, availability, and confidentiality.

  • CVSS V3 rated as High - 7.5 severity.
  • CVSS V2 rated as Medium - 5.4 severity.
    • Solution
    Refer to Red Hat security advisory RHSA-2024:1510 for updates and patch information.
    Vendor References

    CVEs related to QID 243134

    CVE-2023-46809 | CVE-2024-21892 | CVE-2024-22019 |
    Software Advisories
    Advisory ID Software Component Link
    RHSA-2024:1510 Red Hat Enterprise Linux URL Logo access.redhat.com/errata/RHSA-2024:1510
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].